Filing Details
- Accession Number:
- 0000899243-15-000146
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-07-02 16:30:28
- Reporting Period:
- 2015-07-01
- Filing Date:
- 2015-07-02
- Accepted Time:
- 2015-07-02 16:30:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1466301 | Clovis Oncology Inc. | CLVS | Pharmaceutical Preparations (2834) | 900475355 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1051411 | T Erle Mast | C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301 | Executive Vp And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-07-01 | 2,000 | $85.19 | 148,583 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-07-01 | 900 | $86.56 | 147,683 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-07-01 | 100 | $88.01 | 147,583 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $84.78 to $85.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $85.93 to $86.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.
Billionaire Hedge Funds
